8 documents found, page 1 of 1

Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan i...

[No abstract available]

Reply to: RAAS inhibitors in COVID-19: Not all are created equal!

[No abstract available]

VALIDATION OF HIGH RISK CRITERIA IN MEDICATION RECONCILIATION IN MAJOR ORTHOPED...

Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVI...

SARS-CoV-2 infection and its clinical manifestations (COVID-19) quickly evolved to a pandemic and a global public health emergency. The limited effectivity of available treatments aimed at reducing virus replication and the lessons learned from other coronavirus infections (SARS-CoV-1 or NL63) that share the internalization process of SARS-CoV-2, led us to revisit the COVID-19 pathogenesis and potential treatme...

Carbidopa alters tryptophan metabolism in breast cancer and melanoma cells lead...

Carbidopa is used for the treatment of Parkinson’s disease (PD) as an inhibitor of DOPA decarboxylase, and PD patients taking carbidopa have a lower incidence of various tumors, except for breast cancer andmelanoma. Recently, itwas shown that carbidopa inhibits tryptophan-2,3-dioxygenase (TDO) and kynureninase enzymes. In the present study, the effect of carbidopa on the viability and metabolic profile of breas...

Vancomycin therapeutic drug monitoring and population pharmacokinetic models in...

Vancomycin is a fundamental antibiotic in the management of severe Gram-positive infections. Inappropriate vancomycin dosing is associated with therapeutic failure, bacterial resistance and toxicity. Therapeutic drug monitoring (TDM) is acknowledged as an important part of the vancomycin therapy management, at least in specific patient subpopulations, but implementation in clinical practice has been difficult b...

Amino acids in the development of Prodrugs

Although drugs currently used for the various types of diseases (e.g., antiparasitic, antiviral, antibacterial, etc.) are effective, they present several undesirable pharmacological and pharmaceutical properties. Most of the drugs have low bioavailability, lack of sensitivity, and do not target only the damaged cells, thus also affecting normal cells. Moreover, there is the risk of developing resistance against...

Release inhibitory receptors activation favours the A(2A)-adenosine receptor-me...

1 Interactions between A(2A)-adenosine receptors and alpha(2)-, A(1)- and P2- release-inhibitory receptors, on the modulation of noradrenaline release were studied in isolated rat tail artery. Preparations were labelled with [H-3]-noradrenaline, superfused with desipramine-containing medium, and stimulated electrically (100 pulses at 5 Hz or 20 pulses at 50 Hz). 2 Blockade of alpha(2)-autoreceptors with yohimbi...